The commercial success of second-generation radiopharmaceuticals in oncology has re-ignited interest in this modality, resulting in a surge of dealmaking and increased venture financing for companies in the field.
Read MoreWhile psychedelic drugs have been historically stigmatized due to their use as recreational drugs, the commercialization of psychedelics and psychedelic-derived compounds for the treatment of psychiatric and neurological disorders has gained significant momentum over the last 5 years. Two events are seen as watershed moments for the surge of interest in psychedelics.
Read MoreRobotic surgery is primed for an acceleration in activity – both in its clinical utilization as well as its strategic importance to the venture community and consolidators alike.
Given the significant opportunity to grow the overall market, the next wave of exciting robotic surgery innovations has caught the eye of medtech investors.
Read MoreThe clinical pipeline for cell therapies has grown significantly, with growth in allogeneic therapies outpacing autologous approaches. While the late-stage cell therapy pipeline is relatively thin, the FDA predicts by 2025 they will approve 10 to 20 cell and gene therapy products annually. In a new article Back Bay considers the recent surge in VC investments and opportunities for advancement.
Read More